nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2022-2-35-42nnp-1782Research ArticleORIGINAL INVESTIGATIONSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИNew potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation.Новые потенциальные биомаркеры болезни Альцгеймера: маркеры эндотелиальной дисфункции и нейровоспаленияhttps://orcid.org/0000-0002-1190-0886МиночкинА. К.MinochkinA. K.

Алесь Константинович Миночкин

Россия, 197706, Санкт-Петербург, Сестрорецк, ул. Борисова, 9

Россия, 194044, Санкт-Петербург, ул. Академика Лебедева, 6

Ales Konstantinovich Minochkin

9, Borisova St., Sestroretsk, Saint Petersburg 197706, Russia

6, Academician Lebedev St., Saint Petersburg 194044, Russia

alesminochkin@gmail.comhttps://orcid.org/0000-0003-3109-8795ЛобзинВ. Ю.LobzinV. Yu.

Россия, 194044, Санкт-Петербург, ул. Академика Лебедева, 6

Россия, 191015, Санкт-Петербург, ул. Кирочная, 41

6, Academician Lebedev St., Saint Petersburg 194044, Russia

41, Kirochnaya St., Saint Petersburg 191015, Russia

https://orcid.org/0000-0002-5100-5229СушенцеваН. Н.SuchentsevaN. N.

Россия, 197706, Санкт-Петербург, Сестрорецк, ул. Борисова, 9

9, Borisova St., Sestroretsk, Saint Petersburg 197706, Russia

https://orcid.org/0000-0003-1778-0165ПоповО. С.PopovO. S.

Россия, 197706, Санкт-Петербург, Сестрорецк, ул. Борисова, 9

Россия, 199034, Санкт-Петербург, Университетская набережная, 7–9

9, Borisova St., Sestroretsk, Saint Petersburg 197706, Russia

7-9, Universitetskaya Embankment, Saint Petersburg 199034, Russia

https://orcid.org/0000-0002-3853-4185АпалькоС. В.ApalkoS. V.

Россия, 197706, Санкт-Петербург, Сестрорецк, ул. Борисова, 9

9, Borisova St., Sestroretsk, Saint Petersburg 197706, Russia

https://orcid.org/0000-0001-5036-1259ЩербакС. Г.SherbakS. G.

Россия, 197706, Санкт-Петербург, Сестрорецк, ул. Борисова, 9

Россия, 199034, Санкт-Петербург, Университетская набережная, 7–9

9, Borisova St., Sestroretsk, Saint Petersburg 197706, Russia

7-9, Universitetskaya Embankment, Saint Petersburg 199034, Russia

СПб ГБУЗ «Городская больница № 40 Курортного административного района» Минздрава России; ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны РоссииРоссияKurortny Administrative District City Hospital № 40, Ministry of Health of Russia; S.M. Kirov Military Medical Academy, Ministry of Defense of RussiaRussian FederationФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России; ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииРоссияS.M. Kirov Military Medical Academy, Ministry of Defense of Russia; I.I. Mechnikov North-Western State Medical University, Ministry of Health of RussiaRussian FederationСПб ГБУЗ «Городская больница № 40 Курортного административного района» Минздрава РоссииРоссияKurortny Administrative District City Hospital № 40, Ministry of Health of RussiaRussian FederationСПб ГБУЗ «Городская больница № 40 Курортного административного района» Минздрава России; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияKurortny Administrative District City Hospital № 40, Ministry of Health of Russia; Saint Petersburg State UniversityRussian Federation2022170420221423542Copyright © Minochkin A.K., Lobzin V.Y., Suchentseva N.N., Popov O.S., Apalko S.V., Sherbak S.G., 20222022Миночкин А.К., Лобзин В.Ю., Сушенцева Н.Н., Попов О.С., Апалько С.В., Щербак С.Г.Minochkin A.K., Lobzin V.Y., Suchentseva N.N., Popov O.S., Apalko S.V., Sherbak S.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/1782

Alzheimer's disease (AD) is the most common cause of dementia in the elderly. The aim of the work was

Objective

Objective: to determine the relationship between laboratory biomarkers in blood plasma and cerebrospinal fluid (CSF) in patients with AD and indicators of neuropsychological testing.

Patients and methods

Patients and methods. 52 patients with AD were examined, in which the concentration of 90 potential biomarkers were measured in blood plasma and CSF. Neuropsychological assessment included the Mini-Mental State Exam (MMSE), Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA), and etc.

Results and discussion

Results and discussion. Correlations of different strength between the values of biomarkers in blood plasma and CSF and the results of neuropsychological assessment were revealed. A correlation was found between the soluble cell adhesion molecule (sICAM-1) in blood plasma and the largest number of neuropsychological tests sensitive to dementia stages (MoCA, MMSE, FAB) in patients with AD at the dementia stage. A correlation was found between the concentration of growth/differentiation factor 15 and interferon γ in blood plasma and FAB scores in patients with AD. The levels of granulocyte colony-stimulating factor (G-CSF) in CSF were associated with the dementia stage in AD, and the interleukin-1 receptor antagonist (IL-1RA) levels, on the contrary, with stages preceding the development of dementia in AD.

Conclusion

Conclusion. sICAM-1 level in blood plasma, which is a marker of endothelial dysfunction, may be an indicator of the severity of the vascular neurodegenerative process in AD at the dementia stage. G-CSF in the CSF is associated with the dementia stage in AD, and IL-1RA – with the pre-dementia stage of AD, which determines the prospect of their further study as diagnostic markers.

Болезнь Альцгеймера (БА) является наиболее частой причиной деменции у пожилых.

Цель исследования – определение взаимосвязей между лабораторными биомаркерами в плазме крови и цереброспинальной жидкости (ЦСЖ) пациентов с БА и показателями нейропсихологического тестирования.

Пациенты и методы

Пациенты и методы. Были обследованы 52 пациента с БА, у которых изучались концентрация 90 потенциальных биомаркеров в плазме крови и ЦСЖ. Проводилось комплексное нейропсихологическое исследование с использованием Краткой шкалы оценки психического статуса (MMSE), Батареи тестов для оценки лобной дисфункции (FAB), Монреальского теста для оценки когнитивных функций (MoCA) и др.

Результаты и обсуждение

Результаты и обсуждение. Выявлены корреляционные связи разной силы между значениями биомаркеров в плазме крови и ЦСЖ и результатами нейропсихологического тестирования. Обнаружена корреляция растворимой молекулы клеточной адгезии (sICAM-1) в плазме крови с наибольшим количеством нейропсихологических тестов, чувствительных к дементным стадиям (MoCA, MMSE, FAB), у пациентов с БА в стадии деменции. Найдена корреляция концентрации трансформирующего фактора роста 15 и интерферона γ в плазме крови с оценкой по FAB у пациентов с БА. Значения гранулоцитарного колониестимулирующего фактора (G-CSF) в ЦСЖ были ассоциированы со стадией деменции при БА, а антагониста рецептора интерлейкина 1 (IL-1RA) – напротив, со стадиями, предшествующими развитию деменции при БА.

Заключение

Заключение. Уровень sICAM-1 в плазме крови, являющийся маркером эндотелиальной дисфункции, может быть индикатором тяжести сосудисто-нейродегенеративного процесса при БА на стадии деменции. G-CSF в ЦСЖ ассоциируется со стадией деменции при БА, а IL-1RA – с додементной стадией БА, что определяет перспективу их дальнейшего исследования в качестве диагностических маркеров.

болезнь Альцгеймерабиомаркерыдеменциядодементные стадиирастворимая молекула клеточной адгезии (sICAM-1)гранулоцитарный колониестимулирующий факторантагонист рецептора интерлейкина 1Alzheimer's diseasebiomarkersdementiapre-dementia stagessoluble cell adhesion molecule (sICAM-1)granulocyte colonystimulating factorinterleukin-1 receptor antagonistReferencesFDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US); 2016. Available from: www.ncbi.nlm.nih.gov/books/NBK326791/ (accessed 22.09.2017).FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US); 2016. Available from: www.ncbi.nlm.nih.gov/books/NBK326791/ (accessed 22.09.2017).Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018 Feb;243(3):213-21. doi: 10.1177/1535370217750088Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018 Feb;243(3):213-21. doi: 10.1177/1535370217750088Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21.Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21.Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.Molinuevo JL, Gispert JD, Dubois B, et al. The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. J Alzheimers Dis. 2013;36(1):67-77. doi: 10.3233/JAD-130203Molinuevo JL, Gispert JD, Dubois B, et al. The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. J Alzheimers Dis. 2013;36(1):67-77. doi: 10.3233/JAD-130203Bayer AJ. The role of biomarkers and imaging in the clinical diagnosis of dementia. Age Ageing. 2018;0:1-3. doi: 10.1093/ageing/afy004Bayer AJ. The role of biomarkers and imaging in the clinical diagnosis of dementia. Age Ageing. 2018;0:1-3. doi: 10.1093/ageing/afy004Ritchie C, Smailagic N, Noel-Storr AH, et al. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2Ritchie C, Smailagic N, Noel-Storr AH, et al. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2Song F, Poljak A, Smythe GA, Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev. 2009 Oct;61(2):69-80. doi: 10.1016/j.brainresrev.2009.05.003. Epub 2009 May 21.Song F, Poljak A, Smythe GA, Sachdev P. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease. Brain Res Rev. 2009 Oct;61(2):69-80. doi: 10.1016/j.brainresrev.2009.05.003. Epub 2009 May 21.Bazenet C, Lovestone S. Plasma biomarkers for Alzheimer's disease: much needed but tough to find. Biomark Med. 2012 Aug;6(4):441-54. doi: 10.2217/bmm.12.48Bazenet C, Lovestone S. Plasma biomarkers for Alzheimer's disease: much needed but tough to find. Biomark Med. 2012 Aug;6(4):441-54. doi: 10.2217/bmm.12.48Hanon O, Vidal JS, Lehmann S, et al; BALTAZAR study group. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimers Dement. 2018 Jul;14(7):858-68. doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17.Hanon O, Vidal JS, Lehmann S, et al; BALTAZAR study group. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. Alzheimers Dement. 2018 Jul;14(7):858-68. doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17.Britschgi M, Wyss-Coray T. Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol. 2007;82:205-33. doi: 10.1016/S0074-7742(07)82011-3Britschgi M, Wyss-Coray T. Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol. 2007;82:205-33. doi: 10.1016/S0074-7742(07)82011-3Xiu MH, Lin CG, Tian L, et al. Increased IL-3 serum levels in chronic patients with schizophrenia: Associated with psychopathology. Psychiatry Res. 2015 Sep 30;229(1-2):225-9. doi: 10.1016/j.psychres.2015.07.029. Epub 2015 Jul 16.Xiu MH, Lin CG, Tian L, et al. Increased IL-3 serum levels in chronic patients with schizophrenia: Associated with psychopathology. Psychiatry Res. 2015 Sep 30;229(1-2):225-9. doi: 10.1016/j.psychres.2015.07.029. Epub 2015 Jul 16.Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol. 2004 Jun;5(6):575-81. doi: 10.1038/ni1078Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol. 2004 Jun;5(6):575-81. doi: 10.1038/ni1078Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006 Sep;12(9):1005-15. doi: 10.1038/nm1484Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006 Sep;12(9):1005-15. doi: 10.1038/nm1484Skaper SD, Facci L, Zusso M, Giusti P. An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Front Cell Neurosci. 2018 Mar 21;12:72. doi: 10.3389/fncel.2018.00072. Erratum in: Front Cell Neurosci. 2020 Feb 03;13:578.Skaper SD, Facci L, Zusso M, Giusti P. An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Front Cell Neurosci. 2018 Mar 21;12:72. doi: 10.3389/fncel.2018.00072. Erratum in: Front Cell Neurosci. 2020 Feb 03;13:578.Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000 May-Jun;21(3):383-421. doi: 10.1016/s0197-4580(00)00124-xAkiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000 May-Jun;21(3):383-421. doi: 10.1016/s0197-4580(00)00124-xTeixeira AL, Reis HJ, Coelho FM, et al. All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta-amyloid peptide. Biol Psychiatry. 2008 Nov 15;64(10):891-5. doi: 10.1016/j.biopsych.2008.07.019. Epub 2008 Aug 30.Teixeira AL, Reis HJ, Coelho FM, et al. All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta-amyloid peptide. Biol Psychiatry. 2008 Nov 15;64(10):891-5. doi: 10.1016/j.biopsych.2008.07.019. Epub 2008 Aug 30.Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018 Sep 6;4:575-90. doi: 10.1016/j.trci.2018.06.014Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018 Sep 6;4:575-90. doi: 10.1016/j.trci.2018.06.014Chee SEJ, Solito E. The Impact of Ageing on the CNS Immune Response in Alzheimer's Disease. Front Immunol. 2021 Sep 17;12:738511. doi: 10.3389/fimmu.2021.738511Chee SEJ, Solito E. The Impact of Ageing on the CNS Immune Response in Alzheimer's Disease. Front Immunol. 2021 Sep 17;12:738511. doi: 10.3389/fimmu.2021.738511Ogunmokun G, Dewanjee S, Chakraborty P, et al. The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer's Disease. Cells. 2021 Oct 18;10(10):2790. doi: 10.3390/cells10102790Ogunmokun G, Dewanjee S, Chakraborty P, et al. The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer's Disease. Cells. 2021 Oct 18;10(10):2790. doi: 10.3390/cells10102790Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8(4):e60921. doi: 10.1371/journal.pone.0060921. Epub 2013 Apr 8.Krabbe G, Halle A, Matyash V, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8(4):e60921. doi: 10.1371/journal.pone.0060921. Epub 2013 Apr 8.Michelucci A, Heurtaux T, Grandbarbe L, et al. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol. 2009 May 29;210(1-2):3-12. doi: 10.1016/j.jneuroim.2009.02.003. Epub 2009 Mar 9.Michelucci A, Heurtaux T, Grandbarbe L, et al. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol. 2009 May 29;210(1-2):3-12. doi: 10.1016/j.jneuroim.2009.02.003. Epub 2009 Mar 9.Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008 Aug 13;28(33):8354-60. doi: 10.1523/JNEUROSCI.0616-08.2008Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008 Aug 13;28(33):8354-60. doi: 10.1523/JNEUROSCI.0616-08.2008Qin C, Li Y, Wang K. Functional Mechanism of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Animal Models with Alzheimer's Disease: Inhibition of Neuroinflammation. J Inflamm Res. 2021 Sep 17;14:4761-75. doi: 10.2147/JIR.S327538Qin C, Li Y, Wang K. Functional Mechanism of Bone Marrow-Derived Mesenchymal Stem Cells in the Treatment of Animal Models with Alzheimer's Disease: Inhibition of Neuroinflammation. J Inflamm Res. 2021 Sep 17;14:4761-75. doi: 10.2147/JIR.S327538Angiulli F, Conti E, Zoia CP, et al. Blood- Based Biomarkers of Neuroinflammation in Alzheimer's Disease: A Central Role for Periphery? Diagnostics (Basel). 2021 Aug 24;11(9):1525. doi: 10.3390/diagnostics11091525Angiulli F, Conti E, Zoia CP, et al. Blood- Based Biomarkers of Neuroinflammation in Alzheimer's Disease: A Central Role for Periphery? Diagnostics (Basel). 2021 Aug 24;11(9):1525. doi: 10.3390/diagnostics11091525Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec 12;55(11):1621-6. doi: 10.1212/wnl.55.11.1621Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec 12;55(11):1621-6. doi: 10.1212/wnl.55.11.1621Nasreddine ZS, Phillips NA, Bеdirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991.Nasreddine ZS, Phillips NA, Bеdirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991.Llinas-Regla J, Vilalta-Franch J, Lopez-Pousa S, et al. The Trail Making Test. Assessment. 2017 Mar;24(2):183-96. doi: 10.1177/1073191115602552. Epub 2016 Jul 28.Llinas-Regla J, Vilalta-Franch J, Lopez-Pousa S, et al. The Trail Making Test. Assessment. 2017 Mar;24(2):183-96. doi: 10.1177/1073191115602552. Epub 2016 Jul 28.Castilhos RM, Chaves ML. Free and Cued Selective Reminding Test sensitivity. Alzheimers Dement (Amst). 2017 Nov 26;10:75. doi: 10.1016/j.dadm.2017.11.005Castilhos RM, Chaves ML. Free and Cued Selective Reminding Test sensitivity. Alzheimers Dement (Amst). 2017 Nov 26;10:75. doi: 10.1016/j.dadm.2017.11.005Burgette LF, Reiter JP. Multiple imputation for missing data via sequential regression trees. Am J Epidemiol. 2010 Nov 1;172(9):1070-6. doi: 10.1093/aje/kwq260. Epub 2010 Sep 14.Burgette LF, Reiter JP. Multiple imputation for missing data via sequential regression trees. Am J Epidemiol. 2010 Nov 1;172(9):1070-6. doi: 10.1093/aje/kwq260. Epub 2010 Sep 14.Müllner D. Modern hierarchical, agglomerative clustering algorithms. Computer science; 2011. Available from: http://dblp.unitrier.de/db/journals/corr/corr1109.html#abs-1109-2378Müllner D. Modern hierarchical, agglomerative clustering algorithms. Computer science; 2011. Available from: http://dblp.unitrier.de/db/journals/corr/corr1109.html#abs-1109-2378Conte M, Ostan R, Fabbri C, et al. Human Aging and Longevity Are Characterized by High Levels of Mitokines. J Gerontol A Biol Sci Med Sci. 2019 Apr 23;74(5):600-7. doi: 10.1093/gerona/gly153Conte M, Ostan R, Fabbri C, et al. Human Aging and Longevity Are Characterized by High Levels of Mitokines. J Gerontol A Biol Sci Med Sci. 2019 Apr 23;74(5):600-7. doi: 10.1093/gerona/gly153Kim DH, Lee D, Lim H, et al. Effect of growth differentiation factor-15 secreted by human umbilical cord blood-derived mesenchymal stem cells on amyloid beta levels in in vitro and in vivo models of Alzheimer's disease. Biochem Biophys Res Commun. 2018 Oct 12;504(4):933-40. doi: 10.1016/j.bbrc.2018.09.012. Epub 2018 Sep 14.Kim DH, Lee D, Lim H, et al. Effect of growth differentiation factor-15 secreted by human umbilical cord blood-derived mesenchymal stem cells on amyloid beta levels in in vitro and in vivo models of Alzheimer's disease. Biochem Biophys Res Commun. 2018 Oct 12;504(4):933-40. doi: 10.1016/j.bbrc.2018.09.012. Epub 2018 Sep 14.Wu PF, Zhang XH, Zhou P, et al. Growth Differentiation Factor 15 Is Associated With Alzheimer's Disease Risk. Front Genet. 2021 Aug 13;12:700371. doi: 10.3389/fgene.2021.700371Wu PF, Zhang XH, Zhou P, et al. Growth Differentiation Factor 15 Is Associated With Alzheimer's Disease Risk. Front Genet. 2021 Aug 13;12:700371. doi: 10.3389/fgene.2021.700371Wojsiat J, Zoltowska KM, Laskowska-Kaszub K, Wojda U. Oxidant/Antioxidant Imbalance in Alzheimer's Disease: Therapeutic and Diagnostic Prospects. Oxid Med Cell Longev. 2018 Jan 31;2018:6435861. doi: 10.1155/2018/6435861Wojsiat J, Zoltowska KM, Laskowska-Kaszub K, Wojda U. Oxidant/Antioxidant Imbalance in Alzheimer's Disease: Therapeutic and Diagnostic Prospects. Oxid Med Cell Longev. 2018 Jan 31;2018:6435861. doi: 10.1155/2018/6435861Лобзин ВЮ. Сосудисто-нейродегенеративные когнитивные нарушения (патогенез, клинические проявления, ранняя и дифференциальная диагностика): Автореф. дисс. … докт. мед. наук. Санкт-Петербург; 2016. С. 33.Lobzin VYu. Sosudisto-neyrodegenerativnyye kognitivnyye narusheniya (patogenez, klinicheskiye proyavleniya, rannyaya i differentsial'naya diagnostika): Avtoref. diss. … dokt. med. nauk [Vascular-neurodegenerative cognitive disorders (pathogenesis, clinical manifestations, early and differential diagnosis): Abstract of the thesis. diss. … doc. med. sci.]. St. Petersburg; 2016. P. 33 (In Russ.).Taipa R, das Neves SP, Sousa AL, et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. Neurobiol Aging. 2019 Apr;76:125-32. doi: 10.1016/j.neurobiolaging.2018.12.019. Epub 2019 Jan 7.Taipa R, das Neves SP, Sousa AL, et al. Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. Neurobiol Aging. 2019 Apr;76:125-32. doi: 10.1016/j.neurobiolaging.2018.12.019. Epub 2019 Jan 7.Motta C, Finardi A, Toniolo S, et al. Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. J Alzheimers Dis. 2020;76(2):681-9. doi: 10.3233/JAD-191250Motta C, Finardi A, Toniolo S, et al. Protective Role of Cerebrospinal Fluid Inflammatory Cytokines in Patients with Amnestic Mild Cognitive Impairment and Early Alzheimer's Disease Carrying Apolipoprotein E4 Genotype. J Alzheimers Dis. 2020;76(2):681-9. doi: 10.3233/JAD-191250Musella A, Fresegna D, Rizzo FR, et al. 'Prototypical' proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. Expert Opin Ther Targets. 2020 Jan;24(1):37-46. doi: 10.1080/14728222.2020.1709823. Epub 2020 Jan 3.Musella A, Fresegna D, Rizzo FR, et al. 'Prototypical' proinflammatory cytokine (IL-1) in multiple sclerosis: role in pathogenesis and therapeutic targeting. Expert Opin Ther Targets. 2020 Jan;24(1):37-46. doi: 10.1080/14728222.2020.1709823. Epub 2020 Jan 3.Clausen BH, Lambertsen KL, Dagaes-Hansen F, et al. Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol. 2016 May;131(5):775-91. doi: 10.1007/s00401-016-1541-5. Epub 2016 Feb 9.Clausen BH, Lambertsen KL, Dagaes-Hansen F, et al. Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke. Acta Neuropathol. 2016 May;131(5):775-91. doi: 10.1007/s00401-016-1541-5. Epub 2016 Feb 9.Oprica M, Hjorth E, Spulber S, et al. Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med. 2007 Jul-Aug;11(4):810-25. doi: 10.1111/j.1582-4934.2007.00074.xOprica M, Hjorth E, Spulber S, et al. Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med. 2007 Jul-Aug;11(4):810-25. doi: 10.1111/j.1582-4934.2007.00074.xSpulber S, Mateos L, Oprica M, et al. Impaired long term memory consolidation in transgenic mice overexpressing the human soluble form of IL-1ra in the brain. J Neuroimmunol. 2009 Mar 31;208(1-2):46-53. doi: 10.1016/j.jneuroim.2009.01.010. Epub 2009 Feb 10.Spulber S, Mateos L, Oprica M, et al. Impaired long term memory consolidation in transgenic mice overexpressing the human soluble form of IL-1ra in the brain. J Neuroimmunol. 2009 Mar 31;208(1-2):46-53. doi: 10.1016/j.jneuroim.2009.01.010. Epub 2009 Feb 10.

The authors declare that there are no conflicts of interest present.